Wang et al. recently demonstrated that targeting uPAR by CRISPR/Cas9-based genome editing in colon carcinoma HCT8 and multiple-drug resistant KBV200 cell lines resulted in attenuation of malignant phenotype and multidrug resistance [157]. Here, PLAUR is linked to colon carcinoma.